Results 31 to 40 of about 148,501 (250)
Amyotrophic lateral sclerosis and cerebellum
Scientific Reports, 2022 AbstractAmyotrophic lateral sclerosis (ALS) is a devastating, heterogeneous neurodegenerative neuromuscular disease that leads to a fatal outcome within 2–5 years, and yet, a precise nature of the association between its major phenotypes and the cerebellar role in ALS pathology remains unknown.
Kabiljo, R +3 more
openaire +4 more sources
Levosimendan for amyotrophic lateral sclerosis [PDF]
The Lancet Neurology, 2021 Levosimendan is a drug developed and approved in the EU to treat severe heart failure by intravenous administration. Its principal pharmacological effect is to increase cardiac contractility by calcium sensitisation of troponin C. Because of the positive action of the drug on the neuromechanical efficiency and contractile function of the diaphragm in ...
Carvalho, Mamede, Swash, Michael
openaire +4 more sources
The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Frontiers in Neuroscience, 2020 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two diseases that form a broad neurodegenerative continuum. Considerable effort has been made to unravel the genetics of these disorders, and, based on this work, it is now clear ...
Yevgeniya A. Abramzon +3 more
semanticscholar +1 more source
Cervical spinal cord atrophy in amyotrophic lateral sclerosis across disease stages
Annals of Clinical and Translational Neurology, 2023 Objective Spinal cord degeneration is a hallmark of amyotrophic lateral sclerosis. The assessment of gray matter and white matter cervical spinal cord atrophy across clinical stages defined using the King's staging system could advance the understanding ...
Anna Nigri +12 more
doaj +1 more source
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis
Molecular Neurodegeneration, 2020 Since its discovery as a primary component in cytoplasmic aggregates in post-mortem tissue of patients with Amyotrophic Lateral Sclerosis (ALS), TAR DNA Binding Protein 43 kDa (TDP-43) has remained a central focus to understand the disease.
Terry R. Suk, Maxime W. C. Rousseaux
semanticscholar +1 more source
Pain in amyotrophic lateral sclerosis
Клиническая практика, 2019 In this review, we discuss different aspects of pain syndrome in patients with amyotrophic lateral sclerosis: etiology, incidence, pathophysiology and main clinical features.
Vladislav B. Voitenkov, E. V. Ekusheva
doaj +1 more source
Journal of Medical Case Reports, 2011 Introduction Amyotrophic lateral sclerosis is a rapidly progressive, fatal neurodegenerative disorder for which there is no effective treatment. The diagnosis is dependent on the clinical presentation and consistent electrodiagnostic studies.
Venizelos Alexander +2 more
doaj +1 more source
The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. [PDF]
PLoS ONE, 2014 Objective biomarkers for amyotrophic lateral sclerosis would facilitate the discovery of new treatments. The common neurotrophin receptor p75 is up regulated and the extracellular domain cleaved from injured neurons and peripheral glia in amyotrophic ...
Stephanie R Shepheard +4 more
doaj +1 more source
Improving clinical trial outcomes in amyotrophic lateral sclerosis
Nature Reviews Neurology, 2020 Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same historically intransigent problem that has existed since the initial description of the disease in the 1860s — a lack of effective therapies.
M. Kiernan +14 more
semanticscholar +1 more source
Prionoids in amyotrophic lateral sclerosis
Brain Communications, 2022 AbstractAmyotrophic lateral sclerosis (ALS) is the third most frequent neurodegenerative disease after Alzheimer’s and Parkinson’s disease. ALS is characterized by the selective and progressive loss of motoneurons in the spinal cord, brainstem and cerebral cortex.
Gosset, Philippe +3 more
openaire +2 more sources